The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Synergistic antitumor activity of withaferin A combined with oxaliplatin triggers reactive oxygen species-mediated inactivation of the PI3K/AKT pathway in human pancreatic cancer cells
Abstract
Application of oxaliplatin for the treatment of pancreatic cancer (PC) is restricted owing to its toxic side effects and drug resistance. We investigated how withaferin A (WA), a bioactive component isolated from the medicinal plant Withania somnifera, acts synergistically with oxaliplatin on human PC in vitro and in vivo. We found that WA enhanced oxaliplatin-induced growth suppression and apoptosis in PC cells dramatically through a mechanism involving mitochondrial dysfunction and inactivation of the PI3K/AKT pathway. Combination treatment resulted in significant accumulation of intracellular reactive oxygen species (ROS). Pretreatment of cells with the ROS scavenger N-acetylcysteine completely blocked the apoptosis induced by combination treatment, and recovered expression of AKT inactivation, which revealed the important role of ROS in apoptosis and AKT regulation. In vivo, combination therapy showed the strongest anti-tumor effects compared with single agents, without obvious additional toxicity. These results support the notion that combination treatment with oxaliplatin and WA could facilitate development of an effective strategy for PC treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Quercetin-3-rutinoside-7-glucoside, rutin, and isochlorogenic acid B from WS worked better than withanolide and withanone against chief protease of SARS-CoV2 [184].”
From Withania somnifera (L.) Dunal (Ashwagandha): A comprehensive review on ethnopharmacology, pharmacotherapeutics, biomedicinal and toxicological aspects (2021) · cites this paper as [184]
Citations
Cites
1 retracted
Banerjee, S., Wang, Z., Kong, D., & Sarkar, F. H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0838 · Cited by 98
RetractedMitochondrial membrane permeabilization in cell death
Kroemer, G., Galluzzi, L., & Brenner, C. (2007) · Physiological Reviews · doi:10.1152/physrev.00013.2006 · Cited by 3,598
Reactive oxygen species, cellular redox systems, and apoptosis
Circu, M. L., & Aw, T. Y. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.12.022 · Cited by 3,340
Mitochondria and cell death: outer membrane permeabilization and beyond
Tait, S. W. G., & Green, D. R. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2952 · Cited by 2,593
Oettle, H., Post, S., Neuhaus, P., Gellert, K., Langrehr, J. M., Ridwelski, K., Schramm, H., Fahlke, J., Zuelke, C., Burkart, C., et al. (2007) · JAMA · doi:10.1001/jama.297.3.267 · Cited by 2,418
Shimizu, S., Narita, M., Tsujimoto, Y., & Tsujimoto, Y. (1999) · Nature · doi:10.1038/20959 · Cited by 2,178
Redox regulation of cell survival
Trachootham, D., Lu, W., Ogasawara, M. A., Valle, N. R.-D., & Huang, P. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1957 · Cited by 1,781
Targeting Apoptosis Pathways in Cancer Therapy
Ghobrial, I. M., Witzig, T. E., & Adjei, A. A. (2005) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.3.178 · Cited by 1,369
Reactive oxygen species in cancer cells: Live by the sword, die by the sword
Schumacker, P. T. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.015 · Cited by 1,242
Kindler, H. L., Niedzwiecki, D., Hollis, D. R., Sutherland, S., Schrag, D., Hurwitz, H. I., Innocenti, F., Mulcahy, M. F., O'Reilly, E. M., Wozniak, T. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.1386 · Cited by 848
Cited by
Sorted by citations
Natural Products as Anticancer Agents: Current Status and Future Perspectives
Naeem, A., Hu, P., Yang, M. Y., Zhang, J., Liu, Y., Zhu, W., & Zheng, Q. (2022) · Molecules · doi:10.3390/molecules27238367 · Cited by 646
Paul, S., Chakraborty, S., Anand, U., Dey, S., Nandy, S., Ghorai, M., Saha, S. C., Patil, M. T., Kandimalla, R., Proćków, J., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112175 · Cited by 306
Targeting Cdc20 as a novel cancer therapeutic strategy
Wang, L., Zhang, J., Wan, L., Zhou, X., Wang, Z. P., & Wei, W. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.04.002 · Cited by 251
Zhang, H., Pan, Y., Cheung, M., Cao, M. P.-J., Yu, C., Chen, L., Zhan, L., He, Z., & Sun, C. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1320-z · Cited by 176
Phytochemicals in cancer cell chemosensitization: Current knowledge and future perspectives
Khatoon, E., Banik, K., Harsha, C., Sailo, B. L., Thakur, K. K., Khwairakpam, A. D., Vikkurthi, R., Devi, T. B., Gupta, S. C., & Kunnumakkara, A. B. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.014 · Cited by 163
Metadata
- Authors
- Li, X., Zhu, F., Jiang, J., Sun, C., Wang, X., Shen, M., Tian, R., Shi, C., Xu, M., Peng, F., Guo, X., Wang, M., & Qin, R.
- Affiliations
- Tongji Hospital (CN)
- Guiyang Medical University (CN)
- Corresponding author
- Wang, Min
- Qin, Renyi
- ORCID
- Venue
- Cancer Letters
- Publisher
- Elsevier BV
- Published
- 2015-02
- Volume
- 357
- Issue
- 1
- Pages
- 219-230
- ISSN
- 0304-3835 (ISSN-L)
- OpenAlex
- W2032234787
- Cited by
- 116
- References
- 51
- Citations by year
- 2026: 5 · 2025: 2 · 2024: 14 · 2023: 10 · 2022: 9 · 2021: 11 · 2020: 19 · 2019: 11 · 2018: 6 · 2017: 14 · 2016: 8 · 2015: 7
- FWCI
- 20.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Letters (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81272659, 81101621, 81160311, 81372353, 81172064, 81301860)
- National “Eleventh Five-Year” Scientific and Technological Support Projects (2006BAI02A13-402)
- Projects of Science Foundation of Hubei Province (2012FFB02401)
- International S&T Cooperation Projects of China (2014DFA31420)
- Research Fund of Young Scholars for the Doctoral Program of Higher Education of China (20110142120014)
- Topics
- Health Sciences › Medicine › Complementary and alternative medicine › Phytochemicals and Medicinal Plants
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacological Effects of Medicinal Plants
- Keywords
- withaferin A, oxaliplatin, pancreatic cancer, combination chemotherapy, synergistic antitumor effect, reactive oxygen species, PI3K/Akt signaling, apoptosis, mitochondrial dysfunction, N-acetylcysteine, drug resistance, Withania somnifera
- MeSH terms
- Oxaliplatin, Animals, Antineoplastic Combined Chemotherapy Protocols, Drug Synergism, Humans, Male, Mice, Inbred BALB C, Mice, Nude, Organoplatinum Compounds, Pancreatic Neoplasms, Prognosis, Random Allocation, Signal Transduction, Apoptosis, Reactive Oxygen Species, Phosphatidylinositol 3-Kinases, Proto-Oncogene Proteins c-akt, Mice, Withanolides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
